Ranitidine: Patient Guide for Australia
Basic Product Information
| International Nonproprietary Name (INN) | Ranitidine |
|---|---|
| Common Australia Brand Names | Zantac®, Rani 2®, Ausran® (note: availability may be restricted) |
| ATC Code | A02BA02 |
| Available Forms & Strengths | Tablets (150 mg, 300 mg), oral syrup (75 mg/5 mL), injection (50 mg/2 mL—hospital use only; rarely available in the community) |
| Main Manufacturers | GlaxoSmithKline, Alphapharm, multiple generic suppliers in past years |
| Prescription Status (Australia) | Prescription only (Schedule 4). Note: Oral ranitidine supply is currently unavailable/withdrawn in Australia due to ongoing safety reviews since 2021. Hospital stocks may be used for specific cases under restrictions. |
Update (2024): Ranitidine's availability in Australia is affected by ongoing investigations related to nitrosamine impurities. Patients should confirm availability with their healthcare provider or pharmacist.
Mechanism of Action
- In simple terms: Ranitidine works by reducing the amount of acid your stomach produces. It blocks the action of histamine on the acid-producing cells in the stomach lining, making the stomach less acidic and easing symptoms like heartburn and ulcers.
- For specialists: Ranitidine is a selective histamine H2-receptor antagonist. It competes with histamine at parietal cell H2-receptors, inhibiting basal and stimulated gastric acid secretion, both volume and concentration of gastric acid and pepsin.
Pharmacokinetics
- Absorption: Rapid and well absorbed after oral administration, with peak plasma levels at 1–3 hours.
- Metabolism: Minimal first-pass metabolism in the liver; about 30% protein binding.
- Elimination: Mostly excreted unchanged by the kidneys (renal clearance). The half-life is around 2–3 hours in adults with normal renal function.
- Duration of Action: Suppression of acid secretion lasts up to 12 hours following a single dose.
Use in Everyday Life & Best Practices
Ranitidine was widely used in Australia for acid-related conditions until its recent withdrawal. It is still prescribed in rare, specific circumstances.
- Typical adult dose: 150 mg twice daily, or 300 mg once daily (at bedtime) for ulcers, gastro-oesophageal reflux disease (GORD), and heartburn. Maintenance dose for long-term therapy may be as low as 150 mg at night.
- Pediatric dose: Based on weight. Consult your doctor for exact dosing for children.
- How to take: Swallow tablets whole with water. If using syrups, measure carefully using the supplied device.
- Missed dose: Take as soon as remembered unless it's almost time for the next dose. Do not double up doses.
- Who should avoid it: Patients with rare hereditary problems of galactose intolerance, severe renal impairment without dose adjustment, or allergies to ranitidine.
Dosing in the Morning vs Evening
When managing acid-related symptoms, timing can affect symptom relief:
- Once daily (300 mg): Best taken at bedtime. This suppresses nocturnal acid secretion and is effective for healing ulcers.
- Twice daily (150 mg morning & evening): Provides steadier acid suppression through the day and night. Suitable for persistent or severe symptoms.
- Practical tips: If your symptoms are worse at night (such as nocturnal heartburn), bedtime dosing is preferred. Try to take the medicine at the same times daily for best results.
Taking with Food or on an Empty Stomach
- Ranitidine can be taken with or without food.
- Taking after meals may provide extended symptom relief for reflux symptoms common in Australian eating patterns (e.g., large evening meals).
- Tip: Maintain a balanced diet high in fibre, moderate in fat, and avoid known triggers (spicy, fatty foods, coffee, alcohol) for stomach upset.
Interaction Warnings
| Interaction Type | Details |
|---|---|
| Food | Minimal direct interaction; high-protein or high-fat meals may slightly slow absorption but do not alter effectiveness. |
| Alcohol | Possible delayed alcohol metabolism, higher blood alcohol levels; best to use caution. |
| Medications |
|
- Always tell your pharmacist or doctor about all medicines—including non-prescription, herbal, or supplements.
Indications
| Official Therapeutic Indications | Common Off-label Uses |
|---|---|
|
|
Dosing According to Clinical Indications
| Condition | Adults | Pediatrics | Elderly |
|---|---|---|---|
| Peptic ulcer (healing) | 150 mg twice daily or 300 mg at night for 4–8 weeks | 2–4 mg/kg twice daily (max 300 mg per day) | 150 mg once or twice daily (adjust for renal/kidney function) |
| GORD | 150 mg twice daily or 300 mg at night | Same as above | Same as above |
| Prevention (maintenance) | 150 mg at night | As directed, lower dose preferred | 150 mg at night |
| Zollinger-Ellison syndrome | Initial 150 mg 3 times daily, increased as needed | Specialist dosing only | Specialist supervision |
All dosing should only occur under direct medical supervision. Dose adjustments may be needed for patients with kidney (renal) or liver impairment.
Safety Profile & Side Effects
- Common side effects:
- Headache
- Dizziness
- Diarrhoea or constipation
- Fatigue
- Rare but serious effects:
- Allergic reactions (rash, swelling, trouble breathing—seek urgent care)
- Liver enzyme or function abnormalities
- Very rarely, altered mental states (confusion, depression, especially in elderly)
- Pancytopenia or thrombocytopenia (very uncommon blood disorders)
- Warnings:
- Not for long-term use without regular review—prolonged acid suppression may mask underlying stomach cancer symptoms.
- Current issues: Possible presence of NDMA (N-nitrosodimethylamine, a potential carcinogen) has led to caution and withdrawal in Australia pending further review.
Guidelines for Proper Use
- Follow your doctor's and pharmacist's instructions carefully.
- Monitor for side effects, especially if elderly or with pre-existing kidney or liver disease.
- Keep all appointments for review—long-term treatment needs monitoring.
- Maintain a healthy, varied Australian diet low in processed foods and rich in whole grains and vegetables.
- If prescribed, store in original packaging below 25°C, away from light and moisture.
Alternative Treatment Options
- Proton Pump Inhibitors (PPIs): Omeprazole, pantoprazole, esomeprazole, rabeprazole. Widely used, highly effective, considered first-line in many settings. Funded by the PBS (Pharmaceutical Benefits Scheme).
- Other H2-receptor antagonists: Famotidine, nizatidine (famotidine is available in Australia and has not been withdrawn; PBS restrictions may apply).
- Antacids and alginate combinations: Gaviscon®, Mylanta®—for short-term symptom relief; available over the counter.
- Non-medication options: Lifestyle changes such as weight management, elevating head of bed, avoiding late large meals, reducing caffeine, spicy or fatty foods, and cessation of smoking.
Comparative overview: PPIs are generally more effective for healing and symptom relief than H2-blockers like ranitidine, but long-term use of any acid suppression therapy should be reviewed due to possible side effects (e.g., low magnesium, increased infection risk, rare kidney injury).
Legal, Registration, and Reimbursement Status in Australia
- ARTG (Australian Register of Therapeutic Goods): Ranitidine holds entries but remains unavailable for supply as of June 2024.
- Schedule: Schedule 4 (Prescription-only medicine).
- PBS (Pharmaceutical Benefits Scheme): Previously subsidised; current PBS listing inactive (check PBS online).
- Status: Withdrawn from general sale; limited use in hospital settings only.
- Regulatory body: Therapeutic Goods Administration (TGA Australia).
Latest Research and Clinical Guidance (2022–2025)
- Multiple global regulatory agencies, including the TGA and the US FDA, have recommended suspension or withdrawal of ranitidine due to detection of NDMA contamination in certain lots. (TGA safety advisories, 2023)
- Current Australian gastroenterology guidelines recommend using PPIs or alternative H2-blockers for most acid-related disorders (Gastroenterological Society of Australia, 2023).
- Recent studies (Edwards et al., Lancet Gastroenterol Hepatol 2022) confirm ranitidine alternatives provide equal or superior symptom control for reflux esophagitis and peptic ulcer healing, with lower long-term cancer risk.
- Ongoing research is investigating arsenic and NDMA exposure risks via medication contaminants (TGA, FDA advisories 2024–2025).
Availability and Delivery
Note: Ranitidine remains largely unavailable from community pharmacies in Australia as of June 2024. Hospital supply may be arranged in rare, specific cases with specialist oversight.
| Pack Size | Indicative Price (AUD) | Delivery Times (Major Cities) |
|---|---|---|
| 30 tablets (150 mg) | N/A (product suspended) | Unavailable for retail supply |
| 6 x 2 mL injection (50 mg/2 mL) | Hospital stock only | Emergency use only |
- Average delivery timeframes: Product not available for online delivery as of the latest update.
- Sydney, Melbourne, Brisbane, Perth, Adelaide: Not available
- Regional areas: Alternative therapies and advice available via local pharmacies or telehealth consultation.
Frequently Asked Questions (FAQ)
- Is ranitidine still available in Australia?
As of June 2024, ranitidine is not available for sale in Australian pharmacies due to ongoing safety investigations. Alternative treatments are available and should be discussed with your GP or pharmacist. - What should I do if I previously used ranitidine?
Consult your doctor for a review. Alternative medications are effective and widely available for all ranitidine indications. - Is it safe to use old stocks of ranitidine?
No. Due to concerns over NDMA impurities, you should not use expired or previously purchased ranitidine. Safely dispose of any leftover medication at your local pharmacy through the Return Unwanted Medicines project. - What should I use instead of ranitidine for heartburn or ulcers?
Proton pump inhibitors (like omeprazole or pantoprazole) or another H2-blocker (like famotidine) are preferred. Your GP or pharmacist can guide the best choice for you. - Where can I find more information?
Refer to the Therapeutic Goods Administration (TGA) website, or consult your healthcare team.
Summary: Ranitidine was an effective, widely used stomach acid reducer in Australia, but has been suspended from supply since 2020 due to impurity concerns. Alternative therapies are available. Always consult your doctor or pharmacist for tailored advice and medication management.
